Bazid, Abdel-Hamid
Wasfy, Momtaz
Fawzy, Mohamed
Nayel, Mohamed
Abdelmegeid, Mohamed
Thabet, Randa Y.
Yong, Hui Sian
El-Sayed, Magdy M.
Magouz, Asmaa
Badr, Yassien
Funding for this research was provided by:
Damanhour University
Article History
Received: 28 June 2022
Accepted: 8 November 2022
First Online: 3 December 2022
Declarations
:
: Magdy M. El-Sayed is a member of MEVAC’s board of directors. Momtaz Wasfy and Randa Y. Thabet are employees in Middle East for Vaccines (ME VAC<sup>®</sup>). Hui Sian Yong is an employer at Kemin Biologisc<sup>®</sup>; MEVAC® now is a part of Kemin<sup>®</sup>. However, this association has no effect on the study’s design, data analysis, results’ interpretation, or publication decision.
: This study was approved by the Institutional Animal Care and Use Committee of the Faculty of Veterinary Medicine, University of Sadat City, Menoufia, Egypt (Ethical approval number: VUSC-004-1-22).
: Not applicable.
: Not applicable.
: Supplementary files 1 and 2 are showing the ScienSano report, containing information on identity and molecular characterization of the virus used to produce the vaccine.